Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Penning

Showing results (281-290 of 461) with videos related to

Pageof 47
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2008
Evidence for the aldo-keto reductase pathway of polycyclic aromatic trans-dihydrodiol activation in human lung A549 cellsJong-Heum Park, Dipti Mangal, Kirk A Tacka, et al.
Chemical Research in Toxicology|April 28, 2020
Clustering a Chemical Inventory for Safety Assessment of Fragrance Ingredients: Identifying Read-Across Analogs to Address Data GapsMihir S Date, Devin O'Brien, Danielle J Botelho, et al.
The Journal of Biological Chemistry|February 16, 2012
Crystal structure of perakine reductase, founding member of a novel aldo-keto reductase (AKR) subfamily that undergoes unique conformational changes during NADPH bindingLianli Sun, Yixin Chen, Chitra Rajendran, et al.
Journal of Medicinal Chemistry|July 10, 2023
Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft ModelKrishnaiah Maddeboina, Sravan K Jonnalagadda, Ahmed Morsy, et al.
Chemico-Biological Interactions|December 17, 2014
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancerDaniel Tamae, Elahe Mostaghel, Bruce Montgomery, et al.
International Journal of Clinical and Experimental Pathology|June 7, 2012
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinomaValerie L Miller, Hsueh-Kung Lin, Paari Murugan, et al.
Free Radical Biology & Medicine|July 1, 2015
Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative diseaseLauren E Tebay, Holly Robertson, Stephen T Durant, et al.
Chemical Research in Toxicology|April 7, 2012
Metabolism and distribution of benzo[a]pyrene-7,8-dione (B[a]P-7,8-dione) in human lung cells by liquid chromatography tandem mass spectrometry: detection of an adenine B[a]P-7,8-dione adductMeng Huang, Xiaojing Liu, Sankha S Basu, et al.
Cancer Research|March 3, 2006
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancerMichael Stanbrough, Glenn J Bubley, Kenneth Ross, et al.
Molecular and Cellular Endocrinology|January 19, 2006
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitorsTrevor M Penning, Stephan Steckelbroeck, David R Bauman, et al.
Pageof 47

Showing results (281-290 of 461) with videos related to

Sort By:
Pageof 47
Proceedings of the National Academy of Sciences of the United States of America|May 14, 2008
Evidence for the aldo-keto reductase pathway of polycyclic aromatic trans-dihydrodiol activation in human lung A549 cellsJong-Heum Park, Dipti Mangal, Kirk A Tacka, et al.
Chemical Research in Toxicology|April 28, 2020
Clustering a Chemical Inventory for Safety Assessment of Fragrance Ingredients: Identifying Read-Across Analogs to Address Data GapsMihir S Date, Devin O'Brien, Danielle J Botelho, et al.
The Journal of Biological Chemistry|February 16, 2012
Crystal structure of perakine reductase, founding member of a novel aldo-keto reductase (AKR) subfamily that undergoes unique conformational changes during NADPH bindingLianli Sun, Yixin Chen, Chitra Rajendran, et al.
Journal of Medicinal Chemistry|July 10, 2023
Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft ModelKrishnaiah Maddeboina, Sravan K Jonnalagadda, Ahmed Morsy, et al.
Chemico-Biological Interactions|December 17, 2014
The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancerDaniel Tamae, Elahe Mostaghel, Bruce Montgomery, et al.
International Journal of Clinical and Experimental Pathology|June 7, 2012
Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinomaValerie L Miller, Hsueh-Kung Lin, Paari Murugan, et al.
Free Radical Biology & Medicine|July 1, 2015
Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative diseaseLauren E Tebay, Holly Robertson, Stephen T Durant, et al.
Chemical Research in Toxicology|April 7, 2012
Metabolism and distribution of benzo[a]pyrene-7,8-dione (B[a]P-7,8-dione) in human lung cells by liquid chromatography tandem mass spectrometry: detection of an adenine B[a]P-7,8-dione adductMeng Huang, Xiaojing Liu, Sankha S Basu, et al.
Cancer Research|March 3, 2006
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancerMichael Stanbrough, Glenn J Bubley, Kenneth Ross, et al.
Molecular and Cellular Endocrinology|January 19, 2006
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitorsTrevor M Penning, Stephan Steckelbroeck, David R Bauman, et al.
Pageof 47